Prognostic Value of Baseline Serum Neurofilament Light Chain Levels in People with Relapsing Multiple Sclerosis by Prior Treatment Status and DMT Type (P5-1.009)
To assess the prognostic value of baseline serum neurofilament light chain (sNfL) levels in treatment-naïve or participants previously treated with disease-modifying therapies (DMTs) before entering ASCLEPIOS I/II.
Authors
- Scott S. Zamvil (ORCID: https://orcid.org/0000-0003-2720-9915)
- Stefan Bittner (ORCID: https://orcid.org/0000-0003-2179-3655)
- Ibolya Boer
- Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
- Anne H. Cross (ORCID: https://orcid.org/0000-0003-0829-7569)
- Tjalf Ziemssen
- Wenjia Wei
- Alit Bhatt
- Eric Thouvenot
Institutions
- Novartis (Switzerland) (CH)
- University of California, San Francisco (US)
- Johannes Gutenberg University Mainz (DE)
- Washington University in St. Louis (US)
- Oklahoma Medical Research Foundation (US)
- Novartis (India) (IN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208487
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00